We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GPhA Petitions FDA for Same-Name Biosimilars
GPhA Petitions FDA for Same-Name Biosimilars
September 24, 2013
In an effort to avoid confusion that could jeopardize patient safety and access, biosimilars should have the same international nonproprietary name (INN) as the biologic they refer to, GPhA asserts in a citizen petition filed Sept. 17.